JP2024500354A5 - - Google Patents

Info

Publication number
JP2024500354A5
JP2024500354A5 JP2023535392A JP2023535392A JP2024500354A5 JP 2024500354 A5 JP2024500354 A5 JP 2024500354A5 JP 2023535392 A JP2023535392 A JP 2023535392A JP 2023535392 A JP2023535392 A JP 2023535392A JP 2024500354 A5 JP2024500354 A5 JP 2024500354A5
Authority
JP
Japan
Prior art keywords
domain
amino acid
item
terminus
domains
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023535392A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024500354A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/062951 external-priority patent/WO2022125986A1/en
Publication of JP2024500354A publication Critical patent/JP2024500354A/ja
Publication of JP2024500354A5 publication Critical patent/JP2024500354A5/ja
Pending legal-status Critical Current

Links

JP2023535392A 2020-12-10 2021-12-10 ヘテロ二量体化のための直交変異 Pending JP2024500354A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063123915P 2020-12-10 2020-12-10
US63/123,915 2020-12-10
PCT/US2021/062951 WO2022125986A1 (en) 2020-12-10 2021-12-10 Orthogonal mutations for heterodimerization

Publications (2)

Publication Number Publication Date
JP2024500354A JP2024500354A (ja) 2024-01-09
JP2024500354A5 true JP2024500354A5 (cg-RX-API-DMAC7.html) 2024-05-30

Family

ID=81974005

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023535392A Pending JP2024500354A (ja) 2020-12-10 2021-12-10 ヘテロ二量体化のための直交変異

Country Status (10)

Country Link
US (2) US12312418B2 (cg-RX-API-DMAC7.html)
EP (1) EP4259194A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024500354A (cg-RX-API-DMAC7.html)
KR (1) KR20230118612A (cg-RX-API-DMAC7.html)
CN (1) CN116867514A (cg-RX-API-DMAC7.html)
AU (1) AU2021397322A1 (cg-RX-API-DMAC7.html)
CA (1) CA3207821A1 (cg-RX-API-DMAC7.html)
IL (1) IL303518A (cg-RX-API-DMAC7.html)
MX (1) MX2023006899A (cg-RX-API-DMAC7.html)
WO (1) WO2022125986A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023245021A2 (en) * 2022-06-14 2023-12-21 Invenra Inc. Multispecific binding agents that target cd25 and/or ctla4 and uses thereof
WO2025129132A1 (en) * 2023-12-14 2025-06-19 Invenra Inc. Multispecific binding agents that target ctla4 and/or cd25 and uses thereof
WO2025151752A1 (en) 2024-01-10 2025-07-17 Xilio Development, Inc. Masked il-2 cytokines and methods of use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013537416A (ja) * 2010-08-13 2013-10-03 メディミューン リミテッド 変異型Fc領域を含むモノマーポリペプチド及び使用方法
CN103429620B (zh) * 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
EA032681B1 (ru) * 2012-11-27 2019-07-31 Аджоу Юниверсити Индастри-Академик Кооперейшн Фаундейшн ГЕТЕРОДИМЕР Fc ИММУНОГЛОБУЛИНА, СОДЕРЖАЩИЙ ВАРИАНТ ДОМЕНА CH3 ДЛЯ ОБРАЗОВАНИЯ АНТИТЕЛА ИЛИ ГИБРИДНОГО БЕЛКА С ГЕТЕРОМЕРНЫМ Fc С ВЫСОКОЙ ЭФФЕКТИВНОСТЬЮ, СПОСОБ ДЛЯ ЕГО ПОЛУЧЕНИЯ И ИСПОЛЬЗОВАНИЯ
SG11201506451UA (en) * 2013-03-06 2015-09-29 Merrimack Pharmaceuticals Inc Anti-c-met tandem fc bispecific antibodies
JP6724023B2 (ja) * 2015-02-09 2020-07-15 リサーチ ディベロップメント ファウンデーション 改善された補体活性化を示す操作された免疫グロブリンfcポリペプチド
EP3511340B1 (en) * 2016-08-10 2024-10-02 Ajou University Industry-Academic Cooperation Foundation Heterodimeric fc-fused cytokine and pharmaceutical composition comprising the same
DK3529269T3 (da) * 2016-10-19 2026-02-23 Invenra Inc Antistof-konstruktioner
US20200095327A1 (en) * 2017-02-08 2020-03-26 Dragonfly Therapeutics, Inc. Antibody heavy chain variable domains targeting the nkg2d receptor
IL274071B2 (en) * 2017-10-30 2025-10-01 Hoffmann La Roche Method for generating in vivo multispecific antibodies from monospecific antibodies
WO2019204522A1 (en) * 2018-04-17 2019-10-24 Invenra Inc. Binding molecules
PE20210320A1 (es) * 2018-06-01 2021-02-16 Novartis Ag Moleculas de union contra bcma y usos de las mismas
JP7812230B2 (ja) * 2019-04-25 2026-02-09 エフ. ホフマン-ラ ロシュ アーゲー ポリペプチド鎖交換による抗体由来ポリペプチドの生成
MX2022010176A (es) * 2020-02-20 2023-01-16 Win Therapeutics Inc Moléculas de unión biespecíficas a gd2 y b7h2 y métodos de uso.

Similar Documents

Publication Publication Date Title
US20230068801A1 (en) Multispecific antibodies
CN107207592B (zh) 结构域交换的抗体
IL274071B1 (en) Method for in vivo generation of multispecific antibodies from monospecific antibodies
JP2021521781A5 (cg-RX-API-DMAC7.html)
JP2019533441A5 (cg-RX-API-DMAC7.html)
JP2021533779A5 (cg-RX-API-DMAC7.html)
AU2017359813B2 (en) Anti-PD-1/anti-HER2 natural antibody structure-like bispecific antibody of heterodimeric form and preparation thereof
JP2021522162A5 (cg-RX-API-DMAC7.html)
HRP20241775T1 (hr) Bispecifična protutijela koja se specifično vežu na pd1 i lag3
CN111699201B (zh) 抗pd-1/抗her2天然抗体结构的异源二聚双特异性抗体及其制备方法
RU2015145719A (ru) Модифицированные асимметричные антитела, связывающие fc-рецептор, и способы их применения
JP2019536734A5 (cg-RX-API-DMAC7.html)
US20260078202A1 (en) Orthogonal mutations for heterodimerization
KR20210042326A (ko) 조작된 Fc-항원 결합 도메인 작제물에 관련된 조성물 및 방법
BR112021000416A2 (pt) Composições e métodos relacionados a construtos do domínio de ligação fc-antígeno manipulado direcionado a cd38
JP2023501276A5 (cg-RX-API-DMAC7.html)
BR112021000383A2 (pt) Composições e métodos relacionados a construtos do domínio de ligação fc-antígeno manipulado direcionado a pd-l1
BR112021000393A2 (pt) Composições e métodos relacionados a construtos do domínio de ligação fc-antígeno manipulado
KR20210043583A (ko) 조작된 Fc-항원 결합 도메인 작제물에 관련된 조성물 및 방법
RU2023135060A (ru) Антитела, связывающиеся с cd3
JP2022028645A5 (cg-RX-API-DMAC7.html)
RU2025130619A (ru) Биспецифические агонистические антитела к рецептору i типа, подобному рецептору активина а (alk1)
TH2101006347A (th) โปรตีนการจับชนิดไตรสเปซิฟิกและ/หรือไตรวาเลนต์ที่ใช้รูปแบบโดเมนแปรผันได้คู่ แบบไขว้ (codv) สำหรับการบำบัดการติดเชื้อ hiv
NZ772085B2 (en) Anti-CD3 antibodies, anti-CD123 antibodies and bispecific antibodies specifically binding to CD3 and/or CD123
NZ772085A (en) Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123